Aspire Biopharma, Inc. (NASDAQ:PWUP) | WebDisclosure

Switch to English

9888	Sociétés
199066	Mots-clés
129998	Articles
105820	Communiqués

Accueil
Sociétés
Aspire Biopharma, Inc.

COMMUNIQUÉ DE PRESSE

publié le 10/06/2025 à 14:30, il y a 8 mois 8 jours

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer
Michael Howe to become CEO of Aspire Biopharma Holdings, Inc. on June 10, 2025. His extensive career in leading brands and early-stage companies makes him a strategic fit for the role

Healthcare Board Member CEO Michael Howe Aspire Biopharma Holdings, Inc.
BRÈVE

publiée le 28/05/2025 à 14:35, il y a 8 mois 21 jours

Aspire Biopharma dévoile BUZZ BOMB™ : une nouvelle ère dans les compléments pré-entraînement

Technologie Sublinguale Marché Du Fitness Supplément Pré-entraînement BUZZ BOMB™ Livraison De Caféine
BRÈVE

publiée le 28/05/2025 à 14:35, il y a 8 mois 21 jours

Aspire Biopharma Unveils BUZZ BOMB™: A New Era in Pre-Workout Supplements

Sublingual Technology Fitness Market Pre-workout Supplement BUZZ BOMB™ Caffeine Delivery
COMMUNIQUÉ DE PRESSE

publié le 28/05/2025 à 14:30, il y a 8 mois 21 jours

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025
Aspire Biopharma introduces BUZZ BOMB™, a sublingual pre-workout supplement delivering rapid caffeine to support athletes' performance. Six flavors available in convenient single servings. Global pre-workout supplements market on the rise

Aspire Biopharma Pre-workout Supplement Sublingual BUZZ BOMB™ Caffeine
BRÈVE

publiée le 20/05/2025 à 14:35, il y a 8 mois 29 jours

Aspire Biopharma lance un essai de phase 1 sur une formulation d'aspirine à haute dose

Développement Clinique Examen De La FDA Essai De Phase 1 Aspirine À Haute Dose Absorption Sublinguale
BRÈVE

publiée le 20/05/2025 à 14:35, il y a 8 mois 29 jours

Aspire Biopharma Begins Phase 1 Trial of High-Dose Aspirin Formulation

Clinical Development Phase 1 Trial FDA Review High-dose Aspirin Sublingual Absorption
COMMUNIQUÉ DE PRESSE

publié le 20/05/2025 à 14:30, il y a 8 mois 29 jours

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Aspire Biopharma initiates Phase 1 trial for high-dose aspirin formulation in the United States, targeting accelerated approval with positive data anticipated in 3Q 2025

Accelerated Approval Phase 1 Trial FDA Feedback Aspire Biopharma High-dose Aspirin Formulation
BRÈVE

publiée le 08/05/2025 à 14:05, il y a 9 mois 10 jours

Aspire Biopharma to Participate in Sidoti Virtual Investor Conference

Investor Presentation Drug Delivery Technology Sidoti Conference Aspire Biopharma Virtual Meetings
BRÈVE

publiée le 08/05/2025 à 14:05, il y a 9 mois 10 jours

Aspire Biopharma participera à la conférence virtuelle des investisseurs de Sidoti

Presentation Aux Investisseurs Technologie D'administration De Médicaments Conférence De Sidoti Aspire Biopharma Réunions Virtuelles
COMMUNIQUÉ DE PRESSE

publié le 08/05/2025 à 14:00, il y a 9 mois 10 jours

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
Aspire Biopharma to present at Sidoti Virtual Investor Conference on May 21 and host virtual one-on-ones with investors. Company's disruptive drug delivery technology highlighted

Sidoti Virtual Investor Conference Virtual Presentation One-on-one Meetings Drug Delivery Technology Aspire Biopharma

Les Echos

Publié le 18/02/2026 à 18:00, il y a 5 heures 29 minutes

Publication du nombre d’actions composant le capital et du nombre total de droits de vote au 31 janvier 2026
Publié le 18/02/2026 à 18:00, il y a 5 heures 29 minutes

Outstanding Shares and Voting Rights Statement at 31 January 2026
Publié le 18/02/2026 à 17:45, il y a 5 heures 44 minutes

Chiffre d'affaires annuelle
Publié le 18/02/2026 à 17:40, il y a 5 heures 49 minutes

GROUPE ES - Communiqué sur les résultats 2025
Publié le 18/02/2026 à 13:45, il y a 9 heures 44 minutes

NRJ GROUP - Non renouvellement Licence FM Nationale NRJ Suède

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 18/02/2026 à 23:15, il y a 14 minutes

Silver Wolf Mobilizes Drill Rig at Ana Maria
Publié le 18/02/2026 à 22:00, il y a 1 heure 29 minutes

Nextech3D.ai Delivers Q3 +59% YoY Revenue Growth and +20% Sequential Gain With Record 95% Gross Margins; Operating Loss Improved by 46% ($696K) As Company Enters New AI‑Driven Growth Cycle
Publié le 18/02/2026 à 19:10, il y a 4 heures 19 minutes

Secure Blockchain Announces Definitive Agreement to Acquire Agentic Solutions Limited, Private Placement and Debt Settlement
Publié le 18/02/2026 à 15:15, il y a 8 heures 14 minutes

Host of "The Schaftlein Report" on Patriot.TV Delivers Urgent Warning to Trump: 2026 Midterm Course Correction Needed Now
Publié le 18/02/2026 à 15:00, il y a 8 heures 29 minutes

Jaguar Health Announces a Special One-time Stock Dividend

Voir tout ACCESSWIRE

EQS Group

Publié le 18/02/2026 à 22:20, il y a 1 heure 9 minutes

Amrize Closes Acquisition of PB Materials; Aggregates Leader in High-Growth West Texas
Publié le 18/02/2026 à 22:15, il y a 1 heure 14 minutes

Amrize Files Form 10-K for Fiscal Year 2025
Publié le 18/02/2026 à 21:01, il y a 2 heures 28 minutes

North Peak Announces Increase in Size of Its Non-Brokered Private Placement
Publié le 18/02/2026 à 21:00, il y a 2 heures 29 minutes

HHLA records solid growth in an uncertain environment – tax-related one-off effects weigh heavily on net profit
Publié le 18/02/2026 à 20:59, il y a 2 heures 30 minutes

EQS-Adhoc: Hamburger Hafen und Logistik AG: HHLA records solid growth in an uncertain environment – tax-related one-off effects weigh heavily on net profit